2月27日晚间,百济神州有限公司发布业绩快报,2024年实现营业总收入272.14亿元,同比增长56.2%;归属于母公司所有者的净利润亏损49.78亿元,上年同期亏损67.16亿元。报告期内,公司营业收入增加56.2%,主要得益于百悦泽®(泽布替尼胶囊),以及安进授权产品和百泽安®(替雷利珠单抗)的销售增长。同时公告,综合近年来的业务发展趋势,公司预计的中国企业会计准则下2025年全年的经营业绩...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.